Related Experiment Video
Updated: Mar 8, 2026
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
Published on: June 6, 2025
Mixed-phenotype acute leukemia: current challenges in diagnosis and therapy
1aLeukemia Service, Davidoff Cancer Center, Rabin Medical Center, Petah-Tikva, Israel bDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Purpose Of Review:
Mixed-phenotype acute leukemia (MPAL) is a rare disease that poses many diagnostic and therapeutic challenges. Patients with MPAL are considered to have poor outcomes. The difficulties in classifying this leukemia, the lack of prospectively collected data concerning therapeutic outcomes, and rare incidence result in much uncertainty as to the best approach for patients with MPAL.
Recent Findings:
Recent studies demonstrated that most MPALs are associated with cytogenetic abnormalities; genetic sequencing studies disclose a high frequency of somatic mutations in genes encoding epigenetic regulators, tumor suppressors, and transcription factors. The limited available data suggest that higher remission rates are achieved with acute lymphoblastic leukemia-like induction regimens compared with acute myeloid leukemia-type approaches. Allogeneic transplantation in first remission may be associated with improved survival compared with consolidation chemotherapy.
Summary:
Advances in understanding the genetic landscape of MPAL may allow a more biologically driven classification of this heterogeneous group of leukemias in the future that will lead to optimized therapies for individual patients. Most data that inform therapy are based on retrospective, uncontrolled studies; prospective trials that incorporate targeted approaches based on genetics and immunophenotype are needed.
Insights
Mixed-phenotype acute leukemia (MPAL) is a rare, challenging cancer. Current research suggests acute lymphoblastic leukemia-like treatments and early stem cell transplants may improve outcomes for MPAL patients.
Area of Science:
- Hematology
- Oncology
- Leukemia Research
Background:
- Mixed-phenotype acute leukemia (MPAL) presents significant diagnostic and therapeutic challenges.
- Patients with MPAL often experience poor prognoses.
- Uncertainty regarding optimal treatment strategies stems from classification difficulties, limited prospective data, and rare incidence.
Purpose of the Study:
- To review recent findings and summarize the current understanding of Mixed-phenotype acute leukemia.
- To highlight diagnostic and therapeutic challenges associated with MPAL.
- To discuss the implications of recent genetic discoveries for future MPAL classification and treatment.
Main Methods:
- Review of recent cytogenetic and genetic sequencing studies in MPAL.
- Analysis of available data on therapeutic outcomes comparing different induction regimens.
- Evaluation of the role of allogeneic transplantation versus chemotherapy in first remission.
Main Results:
- Most MPAL cases exhibit cytogenetic abnormalities and frequent mutations in epigenetic regulators, tumor suppressors, and transcription factors.
- Acute lymphoblastic leukemia-like induction regimens appear more effective than acute myeloid leukemia-type approaches.
- Allogeneic transplantation in first remission may offer improved survival compared to consolidation chemotherapy.
Conclusions:
- Understanding the genetic landscape of MPAL is crucial for developing biologically driven classifications and personalized therapies.
- Current therapeutic data are largely based on retrospective studies.
- Prospective trials incorporating targeted approaches based on genetics and immunophenotype are essential for advancing MPAL treatment.
More Related Videos
09:01Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
Published on: March 26, 2018
10:49Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 18, 2013
